- Smith A. The socioeconomic aspects and behavioural effects of influenza. In: Wood C, ed. Influenza: strategies for prevention. London: Royal Society of Medicine, 1998: 46–52.
- Perrotta DM, Decker M, Glezen WP. Acute respiratory disease hospitalizations as a measure of impact of epidemic influenza. Am J Epidemiol 1985; 122: 468–76.
- Simonsen L, Clarke MJ, Williamson GD, Stroup DF, Arden NH, Schonberger LB. The impact of influenza epidemics on mortality: introducing a severity index. Am J Public Health 1997; 87: 1944–50.
- Nicholson KG. Human influenza. In: Nicholson KG, Webster RG, Hay AJ, eds. Textbook of influenza. Oxford: Blackwell Science, 1998: 219–66.
- Scholtissek C. Genetic reassortment of human influenza viruses in nature. In: Nicholson KG, ed. Textbook of influenza. Oxford: Blackwell Science, 1998: 120–5.
- Bender C, Hall H, Huang J, Klimov A, Cox N, Hay A, et al. Characterization of the surface proteins of influenza A (H5N1) viruses isolated from humans in 1997–1998. Virology 1999; 254: 115–23.
- De Jong JC, Class ECJ, Osterhaus ADME, Webster RG, Lim WL. A pandemic warning? Nature 1999; 389: 554.
- Claas EC, Osterhaus AD, van Beek R, De Jong JC, Rimmelzwaan GF, Senne DA, et al. Human influenza A H5N1 virus related to a highly pathogenic avian influenza virus. Lancet 1998; 351: 472–7.
- Monto AS, Sullivan KM. Acute respiratory illness in the community. Frequency of illness and the agents involved. Epidemiol Infect 1993; 110: 145–60.
- Nicholson KG. Managing influenza in primary care. Oxford: Blackwell Science, 1999.
- Nichol KL, Lind A, Margolis KL, Murdoch M, McFadden R, Hauge M, et al. The effectiveness of vaccination against influenza in healthy, working adults. N Engl J Med 1995; 333: 889–93.
- Nicholson KG. Socioeconomics of influenza and influenza vaccination in Europe. Pharmacoeconomics 1996; 3 (9 Suppl ): 75–8.
- Prevention and control of influenza: recommendations of the Advisory Committee on Immunization Practices (ACIP). Morb Mortal Wkly Rep MMWR 1998; 47: RR–6.
- Rodriguez WJ, Hall CB, Welliver R, Simoes EA, Ryan ME, Stutman H, et al. Efficacy and safety of aerosolized ribavirin in young children hospitalized with influenza: a double-blind, multicenter, placebo-controlled trial. J Pediatr 1994; 125: 129–35.
- Steinhauer DA. Role of hemagglutinin cleavage for the pathogenicity of influenza virus. Virology 1999; 258: 1–20.
- Colman P. Structure and function of the neuraminidase. Oxford: Blackwell Science, 1998.
- Hay AJ. Immunology of influenza. Oxford: Blackwell Science, 1998.
- Skehel JJ, Waterfield MD. Studies on the primary structure of the influenza virus haemagglutinin. Proc Natl Acad Sci USA 1975; 79: 968–72.
- Cox NJ, Bender CA. The molecular epidemiology of influenza viruses. Semin Virol 1995; 6: 359–70.
- Wang C, Takeuchi K, Pinto LH, Lamb RA. Ion channel activity of influenza A virus M2 protein: characterization of the amantadine block. J Virol 1993; 67: 5585–94.
- Aoki FY. Amantadine and rimantadine. In: Nicholson KG, Webster RG, Hay AJ, eds. Textbook of influenza. Oxford: Blackwell Science, 1998: 219–66.
- Palese P, Compans RW. Inhibition of influenza virus replication in tissue culture by 2-deoxy-2,3-dehydro-N-trifluoroacetylneuraminic acid (FANA): mechanism of action. J Gen Virol 1976; 33: 159–63.
- Meindl P, Tuppy H. 2-Deoxy-2,3-dehydrosialicacids. II. Competitive inhibition of Vibrio cholerae neuraminidase by 2-deoxy-2,3-dehydro-N-acylneuraminic acids. Hoppe Seylers Z Physiol Chem 1969; 350: 1088–92.
- Varghese JN, Laver WG, Colman PM. Structure of the influenza virus glycoprotein antigen neuraminidase at 2.9 A resolution. Nature 1983; 303: 35–40.
- Colman PM, Varghese JN, Laver WG. Structure of the catalytic and antigenic sites in influenza virus neuraminidase. Nature 1983; 303: 41–4.
- von Itzstein M, Wu WY, Kok GB, Pegg MS, Dyason JC, Jin B, et al. Rational design of potent sialidase-based inhibitors of influenza virus replication. Nature 1993; 363: 418–23.
- Hayden FG, Atmar RL, Schilling M, Johnson C, Poretz D, Paar D, et al. Use of the selective oral neuraminidase inhibitor oseltamivir to prevent influenza. N Engl J Med 1999; 341: 1336–43.
- Hayden FG, Treanor JJ, Fritz RS, Lobo M, Betts RF, Miller M, et al. Use of the oral neuraminidase inhibitor oseltamivir in experimental human influenza: randomized controlled trials for prevention and treatment. JAMA 1999; 282: 1240–6.
- Hayden FG, Robson R, Jennings L, Schiff GM, Ipe D, Jackson HC, et al. Efficacy of oral oseltamivir in experimental human influenza B virus infection (Abstract 1670).; 37th Annual Meeting, IDSA 1999: 1079.
- Hart GJ, Bethell RC. 2,3-Didehydro-2,4-dideoxy-4-guanidino-N-acetyl-d-neuraminic acid (4-guanidino-Neu5Ac2en) is a slow-binding inhibitor of sialidase from both influenza A virus and influenza B virus. Biochem Mol Biol Int 1995; 36: 695–703.
- Varghese JN, Epa VC, Colman PM. Three-dimensional structure of the complex of 4-guanidino-Neu5Ac2en and influenza virus neuraminidase. Protein Sci 1995; 4: 1081–7.
- Smith PW, Sollis SL, Howes PD, Cherry PC, Starkey ID, Cobley KN, et al. Dihydropyrancarboxamides related to zanamivir: a new series of inhibitors of influenza virus sialidases. 1. Discovery, synthesis, biological activity, and structure-activity relationships of 4-guanidino- and 4-amino-4H-pyran-6-carboxamides. J Med Chem 1998; 41: 787–97.
- Taylor NR, Cleasby A, Singh O, Skarzynski T, Wonacott AJ, Smith PW, et al. Dihydropyrancarboxamides related to zanamivir: a new series of inhibitors of influenza virus sialidases. 2. Crystallographic and molecular modeling study of complexes of 4-amino-4H-pyran-6-carboxamides and sialidase from influenza virus types A and B. J Med Chem 1998; 41: 798–807.
- Kim CU, Lew W, Williams MA, Wu H, Zhang L, Chen X, et al. Structure–activity relationship studies of novel carbocyclic influenza neuraminidase inhibitors. J Med Chem 1998; 41: 2451–60.
- Kati WM, Saldivar AS, Mohamadi F, Sham HL, Laver WG, Kohlbrenner WE. GS4071 is a slow-binding inhibitor of influenza neuraminidase from both A and B strains. Biochem Biophys Res Commun 1998; 244: 408–13.
- Woods JM, Bethell RC, Coates JA, Healy N, Hiscox SA, Pearson BA, et al. 4-Guanidino-2,4-dideoxy-2,3-dehydro-N-acetylneuraminic acid is a highly effective inhibitor both of the sialidase (neuraminidase) and of growth of a wide range of influenza A and B viruses in vitro. Antimicrob Agents Chemother 1993; 37: 1473–9.
- Thomas GP, Forsyth M, Penn CR, McCauley JW. Inhibition of the growth of influenza viruses in vitro by 4-guanidino-2,4-dideoxy-N-acetylneuraminicacid. Antiviral Res 1994; 24: 351–6.
- Gubareva LV, Penn CR, Webster RG. Inhibition of replication of avian influenza viruses by the neuraminidase inhibitor 4-guanidino-2,4-dideoxy-2,3-dehydro-N-acetylneuraminic acid. Virology 1995; 212: 323–30.
- Ryan DM, Ticehurst J, Dempsey MH, Penn CR. Inhibition of influenza virus replication in mice by GG167 (4-guanidino-2,4-dideoxy-2,3-dehydro-N-acetylneuraminic acid) is consistent with extracellular activity of viral neuraminidase (sialidase). Antimicrob Agents Chemother 1994; 38: 2270–775.
- Ryan DM, Ticehurst J, Dempsey MH. GG167 (4-guanidino- 2,4-dideoxy-2,3-dehydro-N-acetylneuraminic acid) is a potent inhibitor of influenza virus in ferrets. Antimicrob Agents Chemother 1995; 39: 2583–4.
- Gubareva LV, McCullers JA, Bethell RC, Webster RG. Characterization of influenza A/HongKong/156/97 (H5N1) virus in a mouse model and protective effect of zanamivir on H5N1 infection in mice. J Infect Dis 1998; 178: 1592–6.
- McKimm-Breschkin JL, McDonald M, Blick TJ, Colman PM. Mutation in the influenza virus neuraminidase gene resulting in decreased sensitivity to the neuraminidase inhibitor 4-guanidino-Neu5Ac2en leads to instability of the enzyme. Virology 1996; 225: 240–2.
- Staschke KA, Colacino JM, Baxter AJ, Air GM, Bansal A, Hornback WJ, et al. Molecular basis for the resistance of influenza viruses to 4-guanidino-Neu5Ac2en. Virology 1995; 214: 642–6.
- Blick TJ, Tiong T, Sahasrabudhe A, Varghese JN, Colman PM, Hart GJ, et al. Generation and characterization of an influenza virus neuraminidase variant with decreased sensitivity to the neuraminidase-specific inhibitor 4-guanidino- Neu5Ac2en. Virology 1995; 214: 475–84.
- Gubareva LV, Bethell R, Hart GJ, Murti KG, Penn CR, Webster RG. Characterization of mutants of influenza A virus selected with the neuraminidase inhibitor 4-guanidino- Neu5Ac2en. J Virol 1996; 70: 1818–27.
- Gubareva LV, Robinson MJ, Bethell RC, Webster RG. Catalytic and framework mutations in the neuraminidase active site of influenza viruses that are resistant to 4-guanidino-Neu5Ac2en. J Virol 1997; 71: 3385–90.
- Penn CR, Barnett JM, Bethell RC, Fenton R, Gearing KL, Healy N, Jowett AJ. Selection of influenza virus with reduced sensitivity in vitro to the neuraminidase inhibitor GG167 (4-guanidino-Neu5Ac2en): changes in the haemagglutinin may compensate for loss of neuraminidase activity. In: Brown LE, Hampson AW, Webster RG, eds. Options for the control of influenza III. Amsterdam: Elsevier, 1996: 735–40.
- Cass LM, Efthymiopoulos C, Bye A. Pharmacokinetics of zanamivir after intravenous, oral, inhaled or intranasal administration to healthy volunteers. Clin Pharmacokinet 1999; 36: 1–11.
- Cass LM, Brown J, Pickford M, Fayinka S, Newman SP, Johansson CJ, Bye AJ. Pharmacoscintigraphic evaluation of lung deposition of inhaled zanamivir in healthy volunteers. Clin Pharmacokinet 1999; 36: 21–31.
- Gubareva LV, Matrosovich MN, Brenner MK, Bethell RC, Webster RG. Evidence for zanamivir resistance in an immunocompromised child infected with influenza B virus. J Infect Dis 1998; 178: 1257–62.
- Hayden FG, Treanor JJ, Betts RF, Lobo M, Esinhart JD, Hussey EK. Safety and efficacy of the neuraminidase inhibitor GG167 in experimental human influenza. JAMA 1996; 275: 295–9.
- Calfee DP, Peng AW, Cass LM, Lobo M, Hayden FG. Safety and efficacy of intravenous zanamivir in preventing experimental human influenza A virus infection. Antimicrob Agents Chemother 1999; 43: 1616–20.
- Walker JB, Hussey EK, Treanor JJ, Montalvo A Jr, Hayden FG. Effects of the neuraminidase inhibitor zanamavir on otologic manifestations of experimental human influenza. J Infect Dis 1997; 176: 1417–22.
- Hayden FG, Osterhaus AD, Treanor JJ, Fleming DM, Aoki FY, Nicholson KG, et al. GG167 Influenza Study Group. Efficacy and safety of the neuraminidase inhibitor zanamivir in the treatment of influenza virus infections. N Engl J Med 1997; 337: 874–80.
- The MIST (Management of Influenza in the Southern Hemisphere Trialists) Study Group. Randomised trial of efficacy and safety of inhaled zanamivir in treatment of influenza A and B virus infections. Lancet 1998; 352: 1877–81.
- Monto AS, Fleming DM, Henry D, de Groot R, Makela M, Klein T, et al. Efficacy and safety of the neuraminidase inhibitor zanamivir in the treatment of influenza A and B virus infections. J Infect Dis 1999; 180: 254–61.
- Mäkelä MJ, Pauksens K, Rostila T, Fleming DM, Man CY, Keene ON, Webster A. Clinical efficacy and safety of the orally inhaled neuraminidase inhibitor zanamivir in the treatment of influenza: a randomized, double blind, placebo-controlled European study. J Infect 2000; 40: 42–8.
- Relenza: summary of product characteristics. Glaxo Wellcome, January 2000.
- Osterhaus A, Makela MJ, Webster A, Keene O. The efficacy of inhaled zanamivir in the treatment of influenza B (Abstract 0281). 39th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, CA, 1999.
- Monto AS, Webster A, Keene O. Randomised, placebo-controlled studies of inhaled zanamivir in the treatment of influenza A and B: pooled efficacy analysis. J Antimicrob Chemother 1999; 44: 23–9.
- Monto AS, Robinson DP, Herlocher ML, Hinson JM Jr, Elliott MJ, Crisp A. Zanamivir in the prevention of influenza among healthy adults: a randomized controlled trial. JAMA 1999; 282: 31–5.
- Schilling M, Povinelli L, Krause P, Gravenstein M, Am- brozaitis A, Jones HH, et al. Efficacy of zanamivir for chemoprophylaxis of nursing home influenza outbreaks. Vaccine 1998; 16: 1771–4.
- Baltussen RM, Reinders A, Sprenger MJ, Postma MJ, Jager JC, Ament AJ, Leidl RM. Estimating influenza-related hospitalization in The Netherlands. Epidemiol Infect 1998; 121: 129–38.
- Armstrong GL, Conn LA, Pinner RW. Trends in infectious disease mortality in the United States during the 20th century. JAMA 1999; 281: 61–6.
- Snacken R. Control of influenza. Public health policies. Vaccine 1999; 17: S61–3.
- Nguyen-Van-Tam J, Neal K. Clinical effectiveness, policies, and practices for influenza and pneumococcal vaccines. Semin Respir Infect 1999; 14: 184–95.
- Oxford JS, Logan IS, Potter CW. In vivo selection of an influenza A2 strain resistant to amantadine. Nature 1970; 226: 82–3.
- Hayden FG, Belshe RB, Clover RD, Hay AJ, Oakes MG, Soo W. Emergence and apparent transmission of rimantadine-resistant influenza A virus in families. N Engl J Med 1989; 321: 1696–702.
Scandinavian Journal of Infectious Diseases
Volume 33, 2001 - Issue 1